Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.
AstraZeneca plc (LON:AZN) has announced a collaboration and investment agreement with Cellectis, a clinical-stage biotechnology company, to accelerate the development of next generation therapeutics in areas of high unmet need,..
HALEON PLC with ticker (LON:HLN) now has a potential downside of -14.0% according to JP Morgan.JP Morgan set a target price of 280 GBX for the company, which when compared..
GSK plc (LON/NYSE: GSK) has announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders announced that the National Medical Products..
GSK plc (LON/NYSE: GSK) has announced positive preliminary results from its phase III trial [https://clinicaltrials.gov/study/NCT05590403] evaluating the immune response and safety of Arexvy (respiratory syncytial virus vaccine, adjuvanted) in adults..
HALEON PLC with ticker (LON:HLN) now has a potential downside of -16.4% according to JP Morgan.JP Morgan set a target price of 280 GBX for the company, which when compared..
GSK plc (LON/NYSE: GSK) has announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of Jemperli..
HALEON PLC with ticker (LON:HLN) now has a potential downside of -17.4% according to JP Morgan.JP Morgan set a target price of 280 GBX for the company, which when compared..
HALEON PLC with ticker (LON:HLN) now has a potential downside of -18.2% according to JP Morgan.JP Morgan set a target price of 280 GBX for the company, which when compared..
GSK plc (LON/NYSE: GSK) has announced that it has reached an exclusive agreement with Chongqing Zhifei Biological Products, Ltd. (Zhifei) to co-promote GSK’s shingles vaccine, Shingrix, in China for an..
GSK plc (LON/NYSE:GSK) has announced that, further to its announcement on 5 October 2023, GSK has agreed to sell 270m ordinary shares in Haleon plc at a price of 328..
AstraZeneca plc (LON:AZN) has entered into settlement agreements in the product liability litigations related to Nexium and Prilosec. The agreements effectively resolve the product liability claims that are currently pending..
ConvaTec Group PLC with ticker (LON:CTEC) now has a potential upside of 36.5% according to RBC Capital Markets.RBC Capital Markets set a target price of 300 GBX for the company,..
AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 22.2% according to Barclays.Barclays set a target price of 13,500 GBX for the company, which when compared to the..
GSK plc (LON/NYSE: GSK) has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) for the prevention of RSV (respiratory..
AstraZeneca PLC (LON:AZN) has announced that positive high-level results from the TROPION-Breast01 Phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant and clinically meaningful improvement for the primary..
AstraZeneca plc (LON:AZN) Alexion, AstraZeneca Rare Disease, has completed a definitive purchase and licence agreement for a portfolio of preclinical rare disease gene therapy programmes and enabling technologies from Pfizer..
GSK plc with ticker (LON:GSK) now has a potential upside of 13.1% according to Deutsche.Deutsche set a target price of 1,700 GBX for the company, which when compared to the..
AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 3.6% according to Deutsche.Deutsche set a target price of 11,000 GBX for the company, which when compared to the..
ConvaTec Group PLC with ticker (LON:CTEC) now has a potential upside of 35.4% according to RBC Capital Markets.RBC Capital Markets set a target price of 300 GBX for the company,..
AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 27.2% according to Barclays.Barclays set a target price of 13,500 GBX for the company, which when compared to the..
